← Back to Search

Monoclonal Antibodies

PF-07260437 for Solid Tumors (C4431001 Trial)

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through 2 years
Awards & highlights

Summary

This trial is testing a new cancer treatment targeting B7-H4 expressing tumors. The safety and effectiveness of the treatment will be evaluated in adults with advanced breast, ovarian, or endometrial cancer.

Eligible Conditions
  • Breast Cancer
  • Ovarian Tumors
  • Endometrial Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events
Number of participants with clinical adverse events at the recommended dose for expansion
Number of participants with clinically significant laboratory abnormalities
+2 more
Secondary outcome measures
Accumulation Ratio (Rac)
Apparent Oral Clearance (CL/F)
Apparent Oral Clearance of Study Drug (CLss/F)
+20 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Monotherapy dose escalation (Part 1)Experimental Treatment1 Intervention
Participants will receive PF-07260437
Group II: Dose Expansion (Part 2C) - Tumor specific Arm CExperimental Treatment2 Interventions
Participants will receive PF07260437
Group III: Dose Expansion (Part 2B) - Tumor specific Arm BExperimental Treatment2 Interventions
Participants will receive PF-07260437
Group IV: Dose Expansion (Part 2A) - Tumor specific Arm AExperimental Treatment2 Interventions
Participants will receive PF-07260437

Find a Location

Who is running the clinical trial?

PfizerLead Sponsor
4,595 Previous Clinical Trials
12,868,740 Total Patients Enrolled
114 Trials studying Breast Cancer
36,195 Patients Enrolled for Breast Cancer
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,496 Previous Clinical Trials
10,045,349 Total Patients Enrolled
45 Trials studying Breast Cancer
12,527 Patients Enrolled for Breast Cancer

Media Library

PF-07260437 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05067972 — Phase 1
Breast Cancer Research Study Groups: Monotherapy dose escalation (Part 1), Dose Expansion (Part 2C) - Tumor specific Arm C, Dose Expansion (Part 2A) - Tumor specific Arm A, Dose Expansion (Part 2B) - Tumor specific Arm B
Breast Cancer Clinical Trial 2023: PF-07260437 Highlights & Side Effects. Trial Name: NCT05067972 — Phase 1
PF-07260437 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05067972 — Phase 1
~8 spots leftby Jul 2025